Display options
Cite
Tsaur I, Thurn K, Juengel E, et al. Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol. 2016;69(3):247-251doi: 10.5173/ceju.2016.820.
Tsaur, I., Thurn, K., Juengel, E., Oppermann, E., Nelson, K., Thomas, C., Bartsch, G., Oremek, G. M., Haferkamp, A., Rubenwolf, P., & Blaheta, R. A. (2016). Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Central European journal of urology, 69(3), 247-251. https://doi.org/10.5173/ceju.2016.820
Tsaur, Igor, et al. "Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients." Central European journal of urology vol. 69,3 (2016): 247-251. doi: https://doi.org/10.5173/ceju.2016.820
Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA. Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol. 2016;69(3):247-251. doi: 10.5173/ceju.2016.820. Epub 2016 Jun 30. PMID: 27729989; PMCID: PMC5057049.
Copy Download .nbib Format: NLM
Share it on

Cent European J Urol. 2016;69(3):247-251. doi: 10.5173/ceju.2016.820. Epub 2016 Jun 30.

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.

Central European journal of urology

Igor Tsaur, Kristina Thurn, Eva Juengel, Elsie Oppermann, Karen Nelson, Christian Thomas, Georg Bartsch, Gerhard M Oremek, Axel Haferkamp, Peter Rubenwolf, Roman A Blaheta

Affiliations

  1. Mainz University Medical Center, Department of Urology, Mainz, Germany.
  2. University Hospital Frankfurt, Department of Urology, Frankfurt, Germany.
  3. University Hospital Frankfurt, Department of Surgery, Frankfurt, Germany.
  4. University Hospital Frankfurt, Department of Vascular and Endovascular Surgery, Frankfurt, Germany.
  5. University Hospital Frankfurt, Department of Laboratory Medicine, Frankfurt, Germany.
  6. Vitalicum Urology Outpatient Unit, Frankfurt, Germany; contributed equally as senior authors.
  7. University Hospital Frankfurt, Department of Urology, Frankfurt, Germany; contributed equally as senior authors.

PMID: 27729989 PMCID: PMC5057049 DOI: 10.5173/ceju.2016.820

Abstract

INTRODUCTION: Monocyte associated transketolase-like 1 (TKTL1) as a cancer biomarker has become popular with alternative practitioners, but plays no role in conventional medicine. This investigation evaluates the potential of serum TKTL1 as a biomarker for prostate cancer.

MATERIAL AND METHODS: Patients (n = 66) undergoing curative radical prostatectomy (RPE) for biopsy-pro-ven PCa were included in the study. Controls (n = 10) were healthy, age-matched, male volunteers. 10 ml of peripheral blood was drawn from patients several days before surgery and from controls. Serum TKTL1 was measured using the ELISA method.

RESULTS: The median age at tumor diagnosis was 66 years and median serum PSA was 8.0 ng/ml. Nearly 96% of PCas submitted to surgery were clinically significant. Compared to healthy controls, serum TKTL1 was significantly lower in PCa patients (p = 0.0001, effect size indicator r = Z/sqr(n) = 0.4179). No correlation was apparent between serum TKTL1 and serum PSA, Gleason sum, tumor stage or further clinical and pathologic parameters.

CONCLUSIONS: Reduced serum TKTL1 in PCa patients stands in opposition to TKTL1 epitope detection in monocytes (EDIM) based studies, whereby increased TKTL1 in monocytes of tumor patients has been reported. Since serum TKTL1 does not correlate with clinical parameters in the current investigation, further research is needed to clarify whether serum TKTL1 has potential as a biomarker for PCa.

Keywords: TKTL1; biomarker; complementary medicine; diagnosis; prostate cancer

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. Eur Urol. 2005 Sep;48(3):386-99; discussion 398-9 - PubMed
  2. Invest Ophthalmol Vis Sci. 2014 Aug 21;55(10):6178-86 - PubMed
  3. BMC Cancer. 2015 Jun 10;15:2 - PubMed
  4. Nat Rev Cancer. 2004 Nov;4(11):891-9 - PubMed
  5. Eur J Cancer. 2013 Apr;49(6):1374-403 - PubMed
  6. BMC Cancer. 2013 Dec 04;13:569 - PubMed
  7. PLoS One. 2011;6(9):e25323 - PubMed
  8. BJU Int. 2011 Sep;108(6):806-13 - PubMed
  9. Int J Cancer. 2009 Mar 15;124(6):1330-7 - PubMed
  10. Diagn Pathol. 2008 Aug 12;3:35 - PubMed
  11. Endocr Relat Cancer. 2009 Sep;16(3):919-28 - PubMed
  12. Cancer Biol Ther. 2016;17 (2):163-8 - PubMed
  13. Cancer Res Treat. 2015 Apr;47(2):306-12 - PubMed
  14. BMC Cancer. 2016 Feb 22;16:134 - PubMed
  15. Scand J Clin Lab Invest Suppl. 2001;235:68-76 - PubMed
  16. Oral Maxillofac Surg. 2016 Sep;20(3):295-302 - PubMed
  17. Clin Lab. 2005;51(5-6):257-73 - PubMed
  18. Adv Exp Med Biol. 2011;701:123-8 - PubMed
  19. Future Oncol. 2012 Oct;8(10):1349-59 - PubMed
  20. World J Urol. 2015 Oct;33(10):1403-9 - PubMed

Publication Types